Biopharmaceuticals increasingly sit at the center of economic security, where trade policy and biosecurity meet. In 2024–2025, Junghwan Park led a cross-ministerial team integrating twelve government ministries to shape Korea's response to U.S. pharmaceutical trade actions and a national biosecurity posture spanning biopharmaceutical supply chains and bio-clusters.
Given the sensitivity of the subject, the work is described here only at a high level: its substance was coordinating a coherent, whole-of-government position across health, trade, industry, and security authorities.